Phase 2, Randomized, Open-Label Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients With Newly Diagnosed Multiple Myeloma Eligible for High-Dose Chemotherapy and Autologous Stem Cell Transplantation
This research study for patients with newly diagnosed Multiple Myeloma (MM) is looking at the safety and effectiveness of a drug, Daratumumab, when added to a standard of care treatment, Revlimid, Velcade, and dexamethasone (RVd) alone. The study is being done primarily to look at whether or not adding daratumumab to standard of care treatment, (RVd), will help patients with newly diagnosed MM achieve a better response after receiving treatment with RVd, with or without daratumumab, and an autologous stem cell transplant (ASCT).
Newly diagnosed multiple myeloma
- Men and women 18-70 years of age
- Diagnosed with multiple myeloma
- No previous treatment for your disease
18 - 70
Healthy Volunteers Needed
Duration of Participation
You will be in the study for approximately 3-4 years, including long-term follow-up.
Clinical Trials Information Line
Janssen Biotech, Inc.